Title
Category
Credits
Event date
Cost
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens. Bispecific antibodies represent a novel treatment option for heavily pretreated FL, including disease relapse following CAR T-cell therapy.
Management of TP53 Mutated Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients. Recent data have shown that BTK inhibitor-based regimens result in favorable outcomes in patients with previously untreated classical MCL with TP53 mutation. Chimeric antigen receptor (CAR) T-cell therapy also results in favorable response rates in previously treated classical MCL with TP53 mutation.
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities. Although these toxicities are generally reversible, early recognition and implementation of an appropriate management strategy are essential.
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?
  • Non-Hodgkin's Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL). The survival benefit was seen only in a subgroup of patients with non-bulky disease and activated B cell (ABC) subtype.
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL). Sequencing of treatment options for relapsed/refractory DLBCL are based on the timing of relapse and eligibility to receive transplant or chimeric antigen receptor (CAR) T-cell therapy. There is a clear need to educate clinicians about the use of novel targeted therapies in appropriately selected patients, the unique spectrum of treatment-related adverse events, and effective management strategies.